Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
INDV · Nasdaq · United States · Pharmaceutical Preparations
In shortIndivior Pharmaceuticals, Inc. is profitable.
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 21.1% | 87/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 16.9% | 88/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 104.2% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 0.71× | 0/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.46× | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 5.82× | 41/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.70 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -7.5% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | -0.44× | 0/100 |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 4 | 100/100 |
| Revenue growth volatility | 7.3% | 84/100 |
| Operating margin volatility | 18.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 11.2% | 79/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 791 | 901 | 1,093 | 1,188 | 1,239 |
| Cost of revenue | 127 | 151 | 174 | 231 | 246 |
| Gross profit | 664 | 749 | 919 | 957 | 994 |
| Research & development | 52 | 74 | 116 | 107 | 97 |
| Selling, general & admin | 431 | 469 | 565 | 612 | 634 |
| Operating income | 213 | (81) | (152) | 38 | 262 |
| Interest expense | 27 | 27 | 35 | 41 | 45 |
| Pre-tax income | 190 | (89) | (145) | 20 | 239 |
| Income tax | (15) | (44) | (19) | 13 | 29 |
| Net income | 205 | (44) | (126) | 7 | 210 |
| Diluted EPS | $1.35 | −$0.32 | −$0.92 | $0.05 | $1.64 |
| Diluted shares (millions) | 152 | 139 | 137 | 133 | 128 |
−0.70 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 3, 2026